Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart scan bonus: cancer PET may spot inflammation

NCT ID NCT06467968

Knowledge-focused Sponsor: Central Hospital, Nancy, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study adds a heart-focused PET scan to a standard cancer imaging test (Gallium-68-DOTATOC) in 99 adults with neuroendocrine tumors. The goal is to see if the scan can detect heart inflammation linked to age and cardiovascular risk factors. Researchers will also compare scan results with blood markers of heart stress. This is an observational study, not a treatment trial.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Gallium-68-DOTATOC (a radioactive tracer used in PET imaging)
What this could lead to
If successful, this could lead to a new way to detect heart inflammation early using a standard cancer scan, without extra radiation or procedures.
What could go wrong
This is a small, early observational study (99 people) and only looks for correlations, not a treatment. The findings may not apply to everyone or lead to a clear diagnostic tool.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 99 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2023

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Persons who have received complete information on the organization of the research and who have signed the informed consent and: * Age ≥ 18 years old. * Having read and understood the information document. * Affiliated to a social security scheme. Person for whom a 68Ga-DOTATOC PET/CT exam is requested as part of the diagnostic or pre-therapeutic assessment of a neuroendocrine tumour. Exclusion Criteria: Person with * Hypersensitivity during previous use of 68Ga-DOTATOC * Impossibility of performing a PET-CT (patient agitated, confused, etc.). * History of heart disease, * Severe arrhythmia that does not allow the PET synchronized with the ECG * Severe renal insufficiency (GFR \<30 ml/min/1.73 m2) * Treated with a somatostatin analogue. * Cushing's syndrome * Pregnant woman, likely to be or breastfeeding * Adult subject to a legal protection measure (guardianship, curators, legal safeguard) * Person of legal age unable to express their consent * Person deprived of liberty by a judicial or administrative decision * Person, subject to psychiatric care under articles L. 3212-1 and L. 3213-1

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiac inflammation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

inflammation of heart layer neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiac inflammation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Veronique Roch

    RECRUITING

    Vandœuvre-lès-Nancy, 54511, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.